newsfilter
← Latest News
GlobeNewswire·

New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy

IRTC
  • Real-world data presented at HRS 2026 supports shifting from short-duration Holter monitoring to up to 14 days of continuous monitoring with Zio ambulatory ECG devices to reduce missed arrhythmias.
  • A retrospective analysis of 11,051 post-ablation patients found that 26% of atrial fibrillation (AF) recurrences were detected beyond 48 hours, meaning short-duration monitoring would miss these events in a significant proportion of patients.
  • Reliance on 24–48-hour monitoring could lead to up to 1 in 4 patients with true AF recurrence being misclassified as false negatives, impacting anticoagulation decisions based on trials like OCEAN.
  • In a study of 486 pregnant patients, 37.7% had arrhythmias, with 60% of all arrhythmias and 66.7% of clinically significant arrhythmias detected after 48 hours of monitoring.
  • Clinically significant arrhythmias in pregnancy included AF, SVT, VT, pauses, or AV block, occurring in 13.6% of the cohort, with 99.2% of monitoring time yielding analyzable data.
  • Mintu Turakhia, MD, MS, stated that 14 days should be the minimum threshold for post-ablation monitoring because shorter durations lead to false negatives in 30% of cases within the first year.
  • Ridhima Kapoor, MD, highlighted that extended monitoring is critical in pregnancy due to physiologic changes increasing arrhythmia risk, with the majority of significant events occurring after 48 hours.
  • Additional evidence from over 1 million patients shows that 24–48-hour monitoring can miss actionable arrhythmias even in patients with frequent daily symptoms.
  • The data reinforce the clinical value of iRhythm's Zio platform, which combines patch-based ECG monitoring with AI-powered analysis to provide a complete assessment of arrhythmia burden.
  • These findings advocate for a progressive shift in clinical practice toward 14-day continuous, uninterrupted monitoring to better align standards of care with evidence-based assessment.